New targeted therapies in melanoma

Cancer Control

Volumn 20, Issue 4, 2013, Pages 282-288

  Kudchadkar, Ragini R ^a   Gonzalez, Rene ^b   Lewis, Karl ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; COBIMETINIB; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; GLYCOPROTEIN GP 100; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIVOLUMAB; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAF GENE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STAGING; COLITIS; DERMATITIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENDOCRINE DISEASE; GENE MUTATION; HEPATITIS; HUMAN; IMMUNOTOXICITY; INTERSTITIAL PNEUMONIA; KIDNEY CANCER; LUNG CANCER; MELANOMA; METASTATIC MELANOMA; NONHUMAN; ONCOGENE; ONCOGENE N RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; UVEA MELANOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84884787172     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481302000405     Document Type: Article

References (51)

1. Ultraviolet radiation and the INTERSUN Programme. Skin cancers. World Health Organization Web site. http://www.who.int/uv/faq/skincancer/en/index1.html. Accessed June 11, 2013.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042-3047.
4. Balch CM, Gershenwal JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
5. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide vs dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158-166.
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-Dose recombinant Interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985-1993. J Clin Oncol. 1999;17(7):2105-2116.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
8. Wan PT, Ganett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutation of B-RAF. Cell. 2004;116(6):855-867.
9. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109.
10. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823-2830.
11. Eisen T, Ahamd T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase III randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581-586.
12. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
13. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
14. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
15. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol. 2012(suppl);8502.
16. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastes, and other solid tumours: a phase I dose escalation trial. Lancet. 2012;379(9829):1893-1901.
17. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
18. Nathanson KL, Martin AM, Letero R, et al. Tumor genetic analysis of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436. J Clin Oncol. 2011;29(suppl):8051.
19. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750-2760.
20. Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82(3):201-209.
21. Whittaker S, Kirk R, Hayward R, et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Trans Med. 2010;2(35):35ra41.
22. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
23. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-3096.
24. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207-215.
25. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
26. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
27. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
28. Gonzalez R, Ribas A, Daud A, et al. Phase IB study of vemurafenib in combination with MEK inhibitor, GDC-0973, in patients with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7). Vienna, Austria: European Society of Medical Oncology; September 28 to October 2, 2012. Abstract LBA28_PR.
29. Padua RA, Barrass N, Currie GA. A novel transforming gene in a human malignant melanoma cell line. Nature. 1984;311(5987):671-673.
30. Ascierto PA. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAF V600 or NRAS mutations. J Clin Oncol. 2012;30(suppl):8511.
31. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012; 18(2):555-567.
32. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.
33. Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene. 2013. Epub ahead of print.
34. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568-576.
35. Curtin JP, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346.
36. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-2909.
37. Wyman K, Atkins MB, Prieto V, et al. Multi-center phase II trial of highdose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006;106(9):2005-2011.
38. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92(8):1398-1405.
39. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599-602.
40. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynaimc study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-2146.
41. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18(2):555-567.
42. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.
43. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
44. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010;363(13)1290]. N Engl J Med. 2010;363(8):711-723.
45. Maio M, Bondarenko I, Robert C, et al. Four-year survival update of metastatic melanoma patients treated with ipilimumab plus darbazine on phase 3 study CA184024. Ann Oncol. 2012;23(9 suppl):1116PD.
46. Patel SP, Hwu W, Kim KB, et al. Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma. J Clin Oncol. 2012;30(suppl):8514.
47. Patel S, Bassett R, Hwu W, et al. Phase II study of ipilimumab and temozolomide in patients with metastatic melanoma. Ann Oncol. 2012;23(9 suppl):1126P.
48. Hodi FS, Friedlander PA, Atkins MB, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011;29(suppl):8511.
49. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, singlearm phase 2 trial. Lancet Oncol. 2012;13(9):879-886.
50. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
51. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.